血小板计数与中性粒细胞“与”淋巴细胞比值的联合改变可作为晚期头颈部癌症患者的预后因素。
Modified combination of platelet count and neutrophil "to" lymphocyte ratio as a prognostic factor in patients with advanced head and neck cancer.
机构信息
Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
出版信息
Head Neck. 2018 Jun;40(6):1138-1146. doi: 10.1002/hed.25085. Epub 2018 Jan 31.
BACKGROUND
We evaluated the prognostic potential of the combination of platelet count and neutrophil to lymphocyte ratio (COP-NLR) in patients with advanced head and neck cancer.
METHODS
We proposed a modified COP-NLR scoring system defined as follows: score 0 (platelet count level <300 × 10 /L and NLR <3); score 1 (platelet count level ≥300 × 10 /L and NLR <3); and score 2 (NLR ≥3). We assessed whether the modified scoring system had better performance as an indicator of prognosis than the existing COP-NLR scoring system (original and 4-group scores).
RESULTS
A total of 248 patients were enrolled. The Akaike Information Criterion value with the modified COP-NLR score was the smallest among the 3 models. The 3-year survival rates according to the modified COP-NLR scores of 0, 1, and 2 were 80.6%, 59.9%, and 23.8%, respectively.
CONCLUSION
The modified COP-NLR score is a useful prognostic marker in patients with advanced head and neck cancer.
背景
我们评估了血小板计数与中性粒细胞与淋巴细胞比值（COP-NLR）联合在晚期头颈部癌症患者中的预后预测能力。
方法
我们提出了一种改良的 COP-NLR 评分系统，定义如下：评分 0（血小板计数水平<300×10 /L 和 NLR<3）；评分 1（血小板计数水平≥300×10 /L 和 NLR<3）；评分 2（NLR≥3）。我们评估了改良评分系统作为预后指标的表现是否优于现有的 COP-NLR 评分系统（原始和 4 组评分）。
结果
共纳入 248 例患者。改良 COP-NLR 评分的赤池信息量准则值在 3 种模型中最小。改良 COP-NLR 评分 0、1 和 2 对应的 3 年生存率分别为 80.6%、59.9%和 23.8%。
结论
改良的 COP-NLR 评分是晚期头颈部癌症患者有用的预后标志物。
Zotero 插件